Lirentelimab improved disease control among patients with antihistamine-refractory chronic urticaria, finds a new study. Clinical research by a team of medical scientists led by Sabine Altrichter, MD, a dermatologist and allergist from the Berlin Institute of Health in Germany, evaluated 47 patients with chronic urticaria from the U.S. and Germany who had uncontrolled disease that was refractory to antihistamine treatment. In the study, lirentelimab led to the primary efficacy endpoint of Urticaria Control Test score improvement from baseline for all patients. Hives or urticaria is a skin rash triggered by a reaction to food, medicine or other irritants.